Not Signed In -
Omalizumab |
Xolair |
Image:Omalizumab.png Omalizumab Systematic (IUPAC) name ? Identifiers CAS number 242138-07-4 ATC code R03DX05 PubChem ? DrugBank BTD00081 Chemical data Formula C6450H9916N1714O2023S38 Mol. weight 145058.2 g/mol Pharmacokinetic data Bioavailability ? Metabolism ? Half life 26 days Excretion ? Therapeutic considerations Pregnancy cat. ? Legal status Routes ? Xolair® allergic asthma medicaiton. Omaliz ...
Wikipedia - [full article]
Omalizumab Clinical Trials
- The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients with Poorly Controlled Asthma
ClinicalTrials.gov Identifier: NCT00133042 - Active, not recruiting
Asthma
- Omalizumab to Treat Eosinophilic Gastroenteritis
ClinicalTrials.gov Identifier: NCT00084097 - Active, not recruiting
Gastroenteritis
- A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma
ClinicalTrials.gov Identifier: NCT00242359 - Not yet recruiting
Allergy Induced Asthma
- Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma
ClinicalTrials.gov Identifier: NCT00454051 - Active, not recruiting
Asthma
- Efficacy and Safety of Omalizumab in Patients with Severe Persistent Asthma
ClinicalTrials.gov Identifier: NCT00046748 - Completed
Asthma
- Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
ClinicalTrials.gov Identifier: NCT00329381 - Recruiting
Asthma
- Effect of Anti-IgE in Chronic Urticaria
ClinicalTrials.gov Identifier: NCT00130234 - Active, not recruiting
Urticaria
- Efficacy and Safety of Xolair in Children (6 - <12 years) with Moderate-Severe, Inadequately Controlled Allergic Asthma
ClinicalTrials.gov Identifier: NCT00079937 - Active, not recruiting
Asthma
- Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
ClinicalTrials.gov Identifier: NCT00264849 - Recruiting
Asthma
- Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
ClinicalTrials.gov Identifier: NCT00546143 - Recruiting
Asthma
- Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma
ClinicalTrials.gov Identifier: NCT00180011 - Recruiting
Asthma
- Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma
ClinicalTrials.gov Identifier: NCT00286416 - Recruiting
Asthma; Allergic Rhinitis
- Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis
ClinicalTrials.gov Identifier: NCT00396409 - Active, not recruiting
Allergic Asthma
- Xolair in Patients with Chronic Sinusitis
ClinicalTrials.gov Identifier: NCT00117611 - Recruiting
Sinusitis
- Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
ClinicalTrials.gov Identifier: NCT00567476 - Recruiting
Asthma
- Effect of Anti-IgE in Non-Allergic Asthma
ClinicalTrials.gov Identifier: NCT00162773 - Recruiting
Asthma
- Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
ClinicalTrials.gov Identifier: NCT00267202 - Recruiting
Allergic Asthma
- A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma (AQUA)
ClinicalTrials.gov Identifier: NCT00434434 - Recruiting
Allergic Asthma
- A Study to Evaluate the Efficacy of Xolair in Atopic Asthmatics
ClinicalTrials.gov Identifier: NCT00096954 - Recruiting
Asthma
- Six Months, Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation in Adolescents (>12 Years) and Adults With Moderate to Severe Persistent Allergic Asthma
ClinicalTrials.gov Identifier: NCT00500539 - Recruiting
Asthma
- Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria Who Exhibit IgE Against Thyreoperoxidase
ClinicalTrials.gov Identifier: NCT00481676 - Recruiting
Chronic Urticaria
- Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab
ClinicalTrials.gov Identifier: NCT00287378 - Not yet recruiting
Asthma; Allergy
- A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-Induced Asthma
ClinicalTrials.gov Identifier: NCT00495612 - Recruiting
Bronchoconstriction
- Efficacy and Safety of Omalizumab in Bullous Pemphigoid
ClinicalTrials.gov Identifier: NCT00472030 - Recruiting
Bullous Pemphigoid
- Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
ClinicalTrials.gov Identifier: NCT00078195 - Completed
Hay Fever; Hypersensitivity; Allergy; Rhinitis
- Non-Invasive Ways to Evaluate Lung Disease After Treatment with Xolair
ClinicalTrials.gov Identifier: NCT00139152 - Recruiting
Lung Disease
- Omalizumab to Treat Hyper-IgE (Job's) Syndrome
ClinicalTrials.gov Identifier: NCT00260702 - Recruiting
Hyper-IgE Syndrome; Job's Syndrome
- Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma
ClinicalTrials.gov Identifier: NCT00482248 - Completed
Asthma
- Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
ClinicalTrials.gov Identifier: NCT00482508 - Completed
Asthma
- Study of Omalizumab in Moderate to Severe Bronchial Asthma
ClinicalTrials.gov Identifier: NCT00232050 - Completed
Asthma
- A Continued Access Protocol to Provide Xolair to Patients with Severe Allergic Asthma
ClinicalTrials.gov Identifier: NCT00109200 - Completed
Asthma
- An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g
ClinicalTrials.gov Identifier: NCT00109187 - Completed
Asthma
- A Safety and Efficacy Study of Xolair in Peanut Allergy
ClinicalTrials.gov Identifier: NCT00086606 - Terminated
Allergy
Resources
- Omalizumab (Drug Digest)
- Xolair (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
